Why Regeneron Pharmaceutical share price fell on Friday?

REGN 3Q earnings was outstanding. With earnings of 15.37 vs 10.10 est, revenue 3.45B vs 2.82 est. 

Don’t Panic. REGN is still an under value and aggressive growth stocks. Antiviral oral tablet is merly 1 of its products.

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论